论著
ENGLISH ABSTRACT
错配修复缺陷结直肠癌中NTRK基因融合变异的检测及其分子病理特征分析
康红
李杜娟
尤慧晗
向铮
成琼
孔令非
作者及单位信息
·
DOI: 10.3760/cma.j.cn112151-20240709-00445
NTRK gene fusion and molecular pathological characteristics of mismatch repair deficient colorectal cancer
Kang Hong
Li Dujuan
You Huihan
Xiang Zheng
Cheng Qiong
Kong Lingfei
Authors Info & Affiliations
Kang Hong
Department of Pathology, People′s Hospital of Zhengzhou University/People′s Hospital of Henan University, Zhengzhou 450043, China
Li Dujuan
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China
You Huihan
Department of Pathology, People′s Hospital of Zhengzhou University/People′s Hospital of Henan University, Zhengzhou 450043, China
Xiang Zheng
Department of Pathology, People′s Hospital of Zhengzhou University/People′s Hospital of Henan University, Zhengzhou 450043, China
Cheng Qiong
Department of Pathology, People′s Hospital of Zhengzhou University/People′s Hospital of Henan University, Zhengzhou 450043, China
Kong Lingfei
Department of Pathology, People′s Hospital of Zhengzhou University/People′s Hospital of Henan University, Zhengzhou 450043, China
·
DOI: 10.3760/cma.j.cn112151-20240709-00445
0
0
0
0
0
0
PDF下载
APP内阅读
摘要

目的探讨pan-TRK免疫组织化学染色在错配修复缺陷(mismatch repair deficient,dMMR)结直肠癌NTRK基因融合变异检测中的价值,并分析伴有NTRK基因融合dMMR结直肠癌的分子病理特征。

方法收集河南省人民医院病理科2020—2023年诊断为dMMR结直肠癌患者117例的组织蜡块,分别运用免疫组织化学、荧光原位杂交(FISH)、基于DNA/RNA二代测序检测肿瘤组织中pan-TRK蛋白表达情况及融合伴侣基因,进一步探讨pan-TRK染色模式与伴侣基因相关性。

结果117例dMMR结直肠癌甲醛固定石蜡包埋样本均成功进行免疫组织化学和FISH检测。其中免疫组织化学pan-TRK阳性病例共15例(15/117,12.8%):6例肿瘤细胞膜及细胞质弥漫强阳性,2例肿瘤细胞质弥漫微弱颗粒状阳性,2例约5%肿瘤细胞核旁中等强度点状阳性,1例肿瘤细胞质及细胞膜弥漫中等至强颗粒状阳性,1例约60%肿瘤细胞质中等至弱颗粒状阳性,1例约1%的肿瘤细胞核强阳性,1例约3%肿瘤细胞核中等至强阳性,1例弥漫核旁中等强度点状阳性及核周弱颗粒状阳性。6例(6/117,5.1%)FISH检测出NTRK1基因断裂,该6例与pan-TRK弥漫强阳性表达病例一致。基于DNA/RNA二代测序进一步证实6例NTRK1基因断裂的病例均携带TPM3-NTRK1融合基因,同时均具有高频微卫星不稳定性及高肿瘤突变负荷,均未检测到KRAS、NRAS、BRAF V600E及TP53基因突变,4例携带环指蛋白43基因移码突变。其他分子改变包括:3例携带ROS1基因突变,2例同时携带BRAC、ALK、EGFR基因突变,2例携带ATM基因突变,2例携带KIT基因突变,均为无明确意义的错义/移码突变。免疫组织化学检测NTRK基因融合的灵敏度为100.0%,特异度为92.5%,膜/质弥漫强阳性的灵敏度及特异度均为100.0%。

结论pan-TRK蛋白在dMMR结直肠癌中表达模式多样,弥漫强阳性表达高度提示NTRK1基因融合。TPM3-NTRK1基因融合是dMMR结直肠癌中较为常见的NTRK基因融合形式。

结直肠肿瘤;DNA错配修复;免疫组织化学;基因融合;pan-TRK
ABSTRACT

ObjectiveTo investigate the expression pattern of pan-TRK protein in colorectal cancers with NTRK gene fusion and mismatch repair deficient (dMMR) and to analyze its molecular pathological characteristics.

MethodsA total of 117 dMMR colorectal cancers diagnosed in the Department of Pathology of Henan Provincial People′s Hospital, Zhengzhou, China from 2020 to 2023 were collected. Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and DNA/RNA-based next-generation sequencing (NGS) were used to detect pan-TRK protein expression and fusion partner genes in tumors, and to further explore the correlation between pan-TRK staining patterns and partner genes.

ResultsIHC and FISH were performed successfully in formalin-fixed paraffin-embedded tissues from 117 dMMR colorectal cancer patients. There were 15 (15/117, 12.8%) cases with positive pan-TRK, including 6 cases with strong staining in tumor cell membrane and cytoplasm, 2 cases with weakly granular staining in tumor cytoplasm, 2 cases with moderate dot-like staining in near 5% tumor cell nuclei, 1 case with moderately to strongly granular staining in the cytoplasm and membrane of tumor cells, 1 case with moderately to weakly granular staining in about 60% of the tumor cells, 1 case with strongly staining in about 1% of the tumor cells, 1 case with moderately to strongly staining in about 3% of the tumor cells and 1 case with diffuse, moderate para-nuclear dot-like and weakly perinuclear granular staining. NTRK1 gene disruption was detected in 6 cases (6/117, 5.1%) and consistent with diffusely strong expression of pan-TRK. Based on DNA/RNA NGS, it was further confirmed that the 6 cases with NTRK1 gene disruption all carried TPM3-NTRK1 fusion gene, and all had high microsatellite instability and high tumor mutation burden. No KRAS, NRAS, BRAF V600E or TP53 gene mutations were detected. Four patients carried frame shift mutations in RNF43. Other molecular changes included 3 cases with ROS1 gene mutation, 2 cases with BRAC, ALK, and EGFR gene mutations, 2 cases with ATM gene mutation, and 2 cases with KIT gene mutation. These were missense/frame shift mutations that were associated with no clinical significance. The nine pan-TRK-positive cases without NTRK gene fusion detected with DNA-based NGS were further confirmed with RNA-based NGS, and no NTRK gene fusion was found. The sensitivity and specificity of NTRK gene fusion detected using IHC were 100.0% and 92.5%, respectively. The sensitivity and specificity of diffusely strong membranous/cytoplasmic staining were both 100.0%.

ConclusionsPan-TRK protein has various expression patterns in dMMR colorectal cancer. Its diffusely strong expression is highly suggestive of NTRK1 gene fusion. TPM3-NTRK1 gene fusion is a common form of NTRK gene fusion in dMMR colorectal cancer.

Colorectal neoplasms;DNA mismatch repair;Immunohistochemistry;Gene fusion;pan-TRK
Kong Lingfei, Email: mocdef.3ab619gnokfl

Kang Hong and Li Dujuan contributed equally to the article

引用本文

康红,李杜娟,尤慧晗,等. 错配修复缺陷结直肠癌中NTRK基因融合变异的检测及其分子病理特征分析[J]. 中华病理学杂志,2025,54(02):135-141.

DOI:10.3760/cma.j.cn112151-20240709-00445

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
神经营养性受体酪氨酸激酶(NTRK)是负责编码原肌球蛋白相关激酶(TRK)的基因,包括NTRK1、NTRK2、NTRK3,分别位于染色体1q22、9q21、15q25,编码TRK家族蛋白TRKA、TRKB、TRKC。近年研究发现,TRK激酶与多种肿瘤的发生发展有关,对于具有NTRK融合基因表达的患者,TRK是肿瘤治疗的重要靶点,随着拉罗替尼和恩曲替尼在中国获批上市,将靶向治疗纳入治疗方案有可能提高肿瘤患者的生存期和生存质量 1。NTRK基因融合在错配修复缺陷(mismatch repair deficient,dMMR)的结直肠癌中发生率明显高于无错配修复缺陷(mismatch repair perfect,pMMR)的结直肠癌,提示在dMMR型结直肠癌患者中更容易筛选出NTRK基因融合阳性患者,使这部分患者在靶向NTRK治疗中获益 2。由于NTRK基因融合在常见癌症类型中罕见以及融合模式的复杂性等技术问题,在临床实践中有效筛选适合TRK抑制剂治疗的患者,不仅具有重要的意义,也具有较大的挑战性。pan-TRK IHC染色简单、经济、高效,适用于NTRK基因融合突变频率低的癌症类型的大规模筛选 3,但特异度及灵敏度尚存在不足,且关于pan-TRK IHC阳性表达模式与NTRK基因融合之间的相关性研究甚少,本研究旨在探讨dMMR结直肠癌中pan-TRK IHC染色对NTRK基因融合的预测价值,以及其阳性表达的模式及其他相关分子病理改变,以帮助临床快速准确筛选NTRK基因融合阳性病例,并提高对其分子特征的认识。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
岳娟清,蔡磊,李俊磊,. NTRK融合基因在实体瘤中的表达及Trk小分子抑制剂研究进展[J]. 中华病理学杂志, 2020,49(9):972-976. DOI: 10.3760/cma.j.cn112151-20200601-00431 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Wang J , Yi Y , Xiao Y ,et al. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS[J]. Mod Pathol, 2019,32(7):1053-1064. DOI: 10.1038/s41379-019-0212-1 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Xu C , Si L , Wang W ,et al. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China[J]. Thorac Cancer, 2022,13(21):3084-3097. DOI: 10.1111/1759-7714.14644 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Wang H , Li ZW , Ou Q ,et al. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability[J]. Cancer Med, 2022,11(13):2541-2549. DOI: 10.1002/cam4.4561 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
濮晓红,高福平,吴鸿雁,. 结直肠癌中错配修复蛋白缺陷与NTRK基因融合的相关性分析[J]. 中华病理学杂志, 2022,51(2):103-107. DOI: 10.3760/cma.j.cn112151-20210716-00512 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Hondelink LM , Schrader A , Asri Aghmuni G ,et al. The sensitivity of pan-TRK immunohistochemistry in solid tumours: a meta-analysis[J]. Eur J Cancer, 2022,173:229-237. DOI: 10.1016/j.ejca.2022.06.030 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Hechtman JF , Benayed R , Hyman DM ,et al. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions[J]. Am J Surg Pathol, 2017,41(11):1547-1551. DOI: 10.1097/PAS.0000000000000911 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Zhang Z , Pang J , Chen L ,et al. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas[J]. Hum Pathol, 2022,129:21-31. DOI: 10.1016/j.humpath.2022.08.001 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Chou A , Fraser T , Ahadi M ,et al. NTRK gene rearrangements are highly enriched in MLH1 /PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases [J]. Mod Pathol, 2020,33(5):924-932. DOI: 10.1038/s41379-019-0417-3 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Kim JH , Hong JH , Choi YL ,et al. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions[J]. J Pathol, 2021,255(4):399-411. DOI: 10.1002/path.5779 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Wu S , Liu Y , Shi X ,et al. Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant[J]. Dig Liver Dis, 2023,55(12):1757-1764. DOI: 10.1016/j.dld.2023.04.019 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Pietrantonio F , Di NicolantonioF , Schrock AB ,et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer[J]. J Natl Cancer Inst, 2017,109(12). DOI: 10.1093/jnci/djx089 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Guo Y , Guo XL , Wang S ,et al. Genomic alterations of NTRK, POLE, ERBB2, and microsatellite instability status in Chinese patients with colorectal cancer[J]. Oncologist, 2020,25(11):e1671-e1680. DOI: 10.1634/theoncologist.2020-0356 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
孔令非,Email: mocdef.3ab619gnokfl
B

康红:论文撰写、病例收集;李杜娟:论文撰写、数据收集;尤慧晗:数据统计:向铮:实验操作;成琼:分子实验结果判读;孔令非:研究指导、资金支持、论文修改

C

康红和李杜娟对本文有同等贡献

D
康红, 李杜娟, 尤慧晗, 等. 错配修复缺陷结直肠癌中NTRK基因融合变异的检测及其分子病理特征分析[J]. 中华病理学杂志, 2025, 54(2): 135-141. DOI: 10.3760/cma.j.cn112151-20240709-00445.
E
所有作者声明无利益冲突
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号